Nolan succeeding Session as CEO of Taysha
Plus: Carmona named CFO at ADC, and updates from NewAmsterdam, CRISPR, Ikena, CN bio and more
Taysha Gene Therapies Inc. (NASDAQ:TSHA) named Chair Sean Nolan as CEO, and Sukumar “Suku” Nagendran, a director, as president and head of R&D. Nolan, former CEO of gene therapy company AveXis Inc., succeeds company founder RA Session, who has resigned from his operating role but will remain on the board. Nagendran was CMO and president of R&D of Jaguar Gene Therapy LLC. Taysha is developing its two lead AAV-based gene therapies in giant axonal neuropathy and Rett syndrome, which are in Phase I/II trials.
ADC Therapeutics S.A. (NYSE:ADCT) hired Jose “Pepe” Carmona as CFO, succeeding Jenn Creel, who is leaving to pursue other opportunities. Carmona, a 12-year veteran of Novartis AG (SIX:NOVN; NYSE:NVS), was most recently CFO at Rubius Therapeutics Inc. (NASDAQ:RUBY)...